All In Biotech

Drug Trial Radar · NCT06388187

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jun 24, 2024

Primary completion

Apr 22, 2026

Study completion Apr 22, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Conditions

  • Obesity

Interventions

  • CagrilintideDrug

    Participants will receive once-weekly cagrilintide subcutaneously.

  • SemaglutideDrug

    Participants will receive once-weekly semaglutide subcutaneously.

  • PlaceboDrug

    Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
  2. Achievement of ≥5% weight reductionTime frame: From baseline (week 0) to end of treatment (week 68)

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • Aurora FDRC Inc.

    Costa Mesa, California

  • Clinical Trial Res Assoc,Inc

    Plantation, Florida

  • Midwest Inst For Clin Res

    Indianapolis, Indiana

  • Accellacare

    Wilmington, North Carolina

  • Velocity Clinical Res-Dallas

    Dallas, Texas

  • Washington Cntr Weight Mgmt

    Arlington, Virginia

  • Capital Clin Res Ctr,LLC

    Olympia, Washington

  • Ocean West Research Clinic

    Surrey, British Columbia, Canada

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, Canada

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, Canada

  • Hospices Civils de Lyon-Hopital Lyon Sud-1

    Pierre-Bénite, France

  • Hospices Civils de Lyon-Hopital Lyon Sud

    Pierre-Bénite, France

  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec

    Saint-Herblain, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil

    Toulouse, France

  • InnoDiab Forschung GmbH

    Essen, Germany

  • Wendisch - Dahl Hamburg - DZHW

    Hamburg, Germany

  • AmBeNet GmbH

    Leipzig, Germany

  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

    Münster, Germany

  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann

    Witten, Germany

  • The Health Centre

    Bradford on Avon, United Kingdom

  • Southmead Hospital

    Bristol, United Kingdom

  • Addenbrooke's Hospital_Cambridge

    Cambridge, United Kingdom

  • University Hospital Coventry - WISDEM Centre

    Coventry, United Kingdom

  • Staploe Medical Centre

    Soham, United Kingdom

  • Joint Clinical Research Facility - Swansea

    Swansea, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.